ArticleDiscover oncology2025
A novel TRP channel-related prognostic model of glioma based on transcriptomics and single cell sequencing analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Orally available Colivin traps TRPV3 in an inactive state and suppresses intestinal inflammation.The EMBO journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is the most malignant intracranial tumor. Transient receptor potential (TRP) channel family has been found to be involved in malignant progression of many tumors. However, the relationship between TRP channel-related genes (TCRGs) and glioma remains unclear.
methodsGene expression profiles and clinical data of 1,475 glioma patients were obtained from TCGA, CGGA, and GEO databases. Prognostic TCRGs were screened and used to classify the patients. Lasso Cox regression analysis was used to construct a risk model, which was validated in external cohorts, and the patients were stratified into high- and low-risk groups. Immune infiltration and functional enrichment analyses were performed to explore the tumor microenvironment in two groups, while drug sensitivity predictions were conducted. Single-cell RNA sequencing data were analyzed to examine the cell type-specific expression of key model genes. Finally, RT-qPCR was performed on paired glioma and adjacent normal tissues to validate the expression of all model genes.
resultsThirty-seven differentially expressed TCRGs were identified in glioma, of which 30 were associated with patient survival. Consensus clustering revealed three molecular subtypes with distinct prognoses, immune infiltration, and pathway enrichment. A 10-gene (TRPM6, PRKCB, CAMK2G, ADCY5, HTR2A, P2RY2, MAPK13, BDKRB1, PLA2G4D, and TRPV3) prognostic model stratified patients into high- and low-risk groups with significantly different overall survival, validated in external cohorts. High-risk patients exhibited higher immune cell infiltration and were predicted to be more sensitive to drugs including 5-Fluorouracil, Dasatinib, Gemcitabine, and Rapamycin, whereas low-risk patients were more sensitive to Vorinostat, Lapatinib, Gefitinib, and Osimertinib. Single-cell RNA sequencing showed that TRPV3 was expressed in exhausted CD8+ T cells, supporting the model’s relevance to tumor immunity and patient prognosis. RT-qPCR verification indicated that all 10 genes in the model were expressed at lower levels in glioma tissues.
conclusionBased on the expression of TCRGs, we conducted the new subtype classification and a prognostic model for glioma, and is expected to provide theoretical basis for the development of new targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.